Delivery of rivaroxaban and chitosan rapamycin microparticle with dual antithrombosis and antiproliferation functions inhibits venous neointimal hyperplasia

References

• Akkaya G, Bilen Ç, Gençpınar T, et al. (2017). Effects of rivaroxaban on intimal hyperplasia and smooth muscle cell proliferation at the carotid artery anastomosis site in rabbits. Anatol J Cardiol 18:261–5.
   PubMed Web of Science ®Google Scholar
• Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, González-Juanatey JR. (2018). Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol 84:280–91.
   PubMed Web of Science ®Google Scholar
• Arepally GM, Ortel TL. (2006). Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–17.
   PubMed Web of Science ®Google Scholar
• Bai H, Hu H, Guo J, et al. (2017). Polyester vascular patches acquire arterial or venous identity depending on their environment. J Biomed Mater Res A 105:3422–31.
   PubMed Web of Science ®Google Scholar
• Bai H, Lee JS, Chen E, et al. (2017). Covalent modification of pericardial patches for sustained rapamycin delivery inhibits venous neointimal hyperplasia. Sci Rep 7:40142.
   PubMed Web of Science ®Google Scholar
• Bai H, Sun P, Wu H, et al. (2021). The application of tissue-engineered fish swim bladder vascular graft. Commun Biol 4:1153.
   PubMed Web of Science ®Google Scholar
• Bai H, Wang M, Foster TR, et al. (2016). Pericardial patch venoplasty heals via attraction of venous progenitor cells. Physiol Rep 4:e12841.
   PubMedGoogle Scholar
• Bai H, Wang Z, Li M, et al. (2020). Adult human vein grafts retain plasticity of vessel identity. Ann Vasc Surg 68:468–75.
   PubMed Web of Science ®Google Scholar
• Bai H, Wang Z, Li M, et al. (2020). Hyaluronic acid-heparin conjugated decellularized human great saphenous vein patches decrease neointimal thickness. J Biomed Mater Res Part B 108:2417–25.
   Web of Science ®Google Scholar
• Bai H, Wang Z, Li M, et al. (2021). Inhibition of programmed death-1 decreases neointimal hyperplasia after patch angioplasty. J Biomed Mater Res B Appl Biomater 109:269–78.
   PubMed Web of Science ®Google Scholar
• Bai H, Wei S, Sun P, et al. (2021). Biomimetic elastin fiber patch in rat aorta angioplasty. ACS Omega 6:26715–21.
   PubMed Web of Science ®Google Scholar
• Bai H, Xie B, Wang Z, et al. (2021). Application of the tissue-engineered plant scaffold as a vascular patch. ACS Omega 6:11595–601.
   PubMed Web of Science ®Google Scholar
• Chiesa E, Dorati R, Conti B, et al. (2018). Hyaluronic acid-decorated chitosan nanoparticles for CD44-targeted delivery of everolimus. IJMS 19:2310.
   Web of Science ®Google Scholar
• Ding Y, Li X, Zhou M, et al. (2021). Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation. Vascul Pharmacol 136:106818.
   PubMed Web of Science ®Google Scholar
• Gigi R, Salai M, Dolkart O, et al. (2012). The effects of direct factor Xa inhibitor (rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res 53:446–50.
   PubMed Web of Science ®Google Scholar
• Goel SA, Guo LW, Liu B, Kent KC. (2012). Mechanisms of post-intervention arterial remodelling. Cardiovasc Res 96:363–71.
   PubMed Web of Science ®Google Scholar
• Gorzelak-Pabis P, Broncel M, Wojdan K, et al. (2021). Rivaroxaban protects from the oxysterol-induced damage and inflammatory activation of the vascular endothelium. Tissue Barriers 9:1956284.
   PubMed Web of Science ®Google Scholar
• Haybar H, Pezeshki SMS, Saki N. (2019). Platelets in in-stent restenosis: from fundamental role to possible prognostic application. Current Cardiology Reviews 16:285–91.
   Web of Science ®Google Scholar
• Hojnik Podrepsek G, Knez Z, Leitgeb M. (2020). Development of chitosan functionalized magnetic nanoparticles with bioactive compounds. Nanomaterials 10:1913.
   Web of Science ®Google Scholar
• Hristov M, Weber C. (2008). Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 58:148–51.
   PubMed Web of Science ®Google Scholar
• Iwatsuki Y, Kawasaki T, Hayashi K, et al. (2004). Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice. Thromb Haemost 92:1221–8.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Smits PC, Love MP, et al. (2017). Randomized comparison of ridaforolimus- and zotarolimus-eluting coronary stents in patients with coronary artery disease: primary results from the bionics trial (bionir ridaforolimus-eluting coronary stent system in coronary stenosis). Circulation 136:1304–14.
   PubMed Web of Science ®Google Scholar
• Kaplovitch E, Eikelboom JW, Dyal L, et al. (2020). Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol 6:21–9.
   Web of Science ®Google Scholar
• Kayssi A, Al-Atassi T, Oreopoulos G, Cochrane Vascular Group, et al. (2016). Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. The Cochrane Database of Systematic Reviews 2016:CD011319.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. (2016). Antithrombotic therapy for vte disease: CHEST guideline and expert panel report. Chest 149:315–52.
   PubMed Web of Science ®Google Scholar
• Krauel K, Hackbarth C, Fürll B, Greinacher A. (2012). Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood 119:1248–55.
   PubMed Web of Science ®Google Scholar
• Krupiczojc MA, Scotton CJ, Chambers RC. (2008). Coagulation signalling following tissue injury: focus on the role of factor Xa. Int J Biochem Cell Biol 40:1228–37.
   PubMed Web of Science ®Google Scholar
• Lee T, Roy-Chaudhury P. (2009). Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. Adv Chronic Kidney Dis 16:329–38.
   PubMed Web of Science ®Google Scholar
• Li L, Liu W, Zhao Y, et al. (2020). Dual-peptide-functionalized nanofibrous scaffolds recruit host endothelial progenitor cells for vasculogenesis to repair calvarial defects. ACS Appl Mater Interfaces 12:3474–93.
   PubMed Web of Science ®Google Scholar
• Liang Y, Wang Y, Wang L, et al. (2021). Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer. Bioact Mater 6:433–46.
   PubMed Web of Science ®Google Scholar
• Liu S, Hu Y, Tao R, et al. (2019). Immobilization of fibronectin-loaded polyelectrolyte nanoparticles on cardiovascular material surface to improve the biocompatibility. Biomed Res Int 2019:5478369.
   PubMed Web of Science ®Google Scholar
• Liu Y, Nelson T, Cromeens B, et al. (2016). HB-EGF embedded in PGA/PLLA scaffolds via subcritical CO2 augments the production of tissue engineered intestine. Biomaterials 103:150–9.
   PubMed Web of Science ®Google Scholar
• Mehta RH, Ferguson TB, Lopes RD, Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators, et al. (2011). Project of ex-vivo vein graft engineering via transfection, I. V. I., saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the project of ex-vivo vein graft engineering via transfection (PREVENT) IV trial. Circulation 124:280–8.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Honda Y. (2018). A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice. J Thromb Thrombolysis 46:95–101.
   PubMed Web of Science ®Google Scholar
• Muto A, Fitzgerald TN, Pimiento JM, et al. (2007). Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg 45 Suppl A:A15–24.
   PubMed Web of Science ®Google Scholar
• Patil SB, Jackman LE, Francis SE, et al. (2010). Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima. ATVB 30:2385–91.
   Google Scholar
• Păun IA, Mustăciosu CC, Popescu RC, et al. (2020). Collagen/chitosan functionalization of complex 3d structures fabricated by laser direct writing via two-photon polymerization for enhanced osteogenesis. IJMS 21:6426.
   Web of Science ®Google Scholar
• Perzborn E, Strassburger J, Wilmen A, et al. (2005). In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939–an oral, direct factor Xa inhibitor. J Thromb Haemost 3:514–21.
   PubMed Web of Science ®Google Scholar
• Quint C. (2020). Tissue-engineered vessel derived from human fibroblasts with an electrospun scaffold. J Tissue Eng Regen Med 14:1652–60.
   PubMed Web of Science ®Google Scholar
• Roehrig S, Straub A, Pohlmann J, et al. (2005). Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 48:5900–8.
   PubMed Web of Science ®Google Scholar
• Sareethammanuwat M, Boonyeun S, Arpornmaeklong P. (2020). Effects of beta-tricalcium phosphate nanoparticles on the properties of a thermosensitive chitosan/collagen hydrogel and controlled release of quercetin. J Biomed Mater Res Part A 109:1147–59.
   PubMed Web of Science ®Google Scholar
• Sartori M, Favaretto E, Cini M, et al. (2015). Rivaroxaban in the treatment of heparin-induced thrombocytopenia. J Thromb Thrombolysis 40:392–4.
   PubMed Web of Science ®Google Scholar
• Seki K, Mizuno Y, Sakashita T, et al. (2017). Demeanor of rivaroxaban in activated/inactivated FXa. J Pharmacol Sci 133:156–61.
   PubMed Web of Science ®Google Scholar
• Sun P, Wang Z, Liu W, et al. (2021). Programmed death-1 mediates venous neointimal hyperplasia in humans and rats. Aging 13:16656–66.
   PubMedGoogle Scholar
• Tardy-Poncet B, Piot M, Montmartin A, et al. (2015). Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban. Thromb Haemost 114:652–4.
   PubMed Web of Science ®Google Scholar
• Tepe G, Gogebakan O, Redlich U, et al. (2017). Angiographic and clinical outcomes after treatment of femoro-popliteal lesions with a novel paclitaxel-matrix-coated balloon catheter. Cardiovasc Intervent Radiol 40:1535–44.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu SJ, Zhang XQ, et al. (2019). Effects of degradation products of biomedical magnesium alloys on nitric oxide release from vascular endothelial cells. Med Gas Res 9:153–9.
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Chong BH, Greinacher A. (1998). Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1–7.
   PubMed Web of Science ®Google Scholar
• Wei S, Li J. a, He H, et al. (2022). A three-layered hydrogel patch with hierarchy releasing of PLGA nanoparticle drugs decrease neointimal hyperplasia. Smart Materials in Medicine 3:139–47.
   Google Scholar
• Xie B, Bai X, Sun P, et al. (2021). A novel plant leaf patch absorbed with IL-33 antibody decreases venous neointimal hyperplasia. Front Bioeng Biotechnol 9:742285.
   PubMed Web of Science ®Google Scholar
• Yuan XB, Yuan YB, Jiang W, et al. (2008). Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 349:241–8.
   PubMed Web of Science ®Google Scholar